Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Pulmonary Hypertension, July 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 161 articles: HTML format

Single Articles

1. WANG Y, Wang X, Zhang Y, Lin L, et al
   Molecular mechanisms of EPAS1 in regulating pulmonary vascular remodeling in COPD: a review.
   Mol Biol Rep. 2026;53:1092.
   PubMed    
   Abstract available
   
   

2. WANG J, Xi L, Tao X, Li H, et al
   Evaluation of Pulmonary Artery Flow Reserve in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Pilot Study.
   J Am Heart Assoc. 2026 Jul 3:e047624. doi: 10.1161/JAHA.125.047624.
   PubMed    
   Abstract available
   
   

3. GOZDECKI L, Belkin MN
   Picking Up the Tempo on Treatment of Combined Post- and Pre-capillary Pulmonary Hypertension: Viewpoint on the CADENCE Trial.
   US Cardiol. 2026;20:e11.
   PubMed    
   
   
   

4. DUSIK M, Havranek S, Fingrova Z, Jansa P, et al
   Long-term follow-up of patients with pulmonary hypertension after catheter ablation of atrial fibrillation and atrial tachycardia.
   Front Cardiovasc Med. 2026;13:1826752.
   PubMed    
   Abstract available
   
   

5. LI T, Zhang S, Aluquin V, Donnelly A, et al
   Early Tracheal and Salivary miRNAs in Extremely Preterm Infants Predict BPD-related Pulmonary Hypertension.
   bioRxiv [Preprint]. 2026 Jun 23:2026.06.17.732493.
   PubMed    
   Abstract available
   
   

6. CLINTON IW, Coursen JC, Rosen DT, Suresh K, et al
   Metabolomic Network Analysis Reveals Reorganization of Lipid and Steroid Programs Linked to Right Ventricular-Pulmonary Vascular Function in Pulmonary Hypertension.
   bioRxiv [Preprint]. 2026 Jun 22:2026.06.16.732773.
   PubMed    
   Abstract available
   
   

7. IKEDA N, Iijima R, Hara H
   Retrograde Balloon Pulmonary Angioplasty for Otherwise Uncrossable Lesions in Chronic Thromboembolic Pulmonary Hypertension.
   Catheter Cardiovasc Interv. 2026 Jul 2. doi: 10.1002/ccd.70725.
   PubMed    
   Abstract available
   
   

8. 
   Correction to "Lycopene Ameliorates Hypoxic Pulmonary Hypertension via Suppression of Oxidative Stress".
   Oxid Med Cell Longev. 2026;2026:e9847903.
   PubMed    
   
   
   

9. GONG LJ, Huang W, Zheng RX, Zhang Y, et al
   [Junren Bufei Yixin Granules ameliorates hypoxic pulmonary hypertension by regulating RELM-beta/SLC7A11/GPX4 signaling pathway].
   Zhongguo Zhong Yao Za Zhi. 2026;51:2588-2599.
   PubMed    
   Abstract available
   
   

10. WANG D, Huang N, Cai M, Huang R, et al
    Corrigendum to "Nitazoxanide reverses pulmonary vascular remodeling in pulmonary hypertension by targeting the IMPA1-RAGE signaling axis" [Toxicology and Applied Pharmacology 507 (2026) 117657].
    Toxicol Appl Pharmacol. 2026 Jul 2:117932. doi: 10.1016/j.taap.2026.117932.
    PubMed    
    
    
    

11. WILSON WM, Aldweib N, Celermajer DS, Opotowsky AR, et al
    Pulmonary Hypertension in Adults With a Systemic Right Ventricle (Biventricular Circulation).
    JACC Adv. 2026;5:102974.
    PubMed    
    Abstract available
    
    

12. ROJAS CHAVERRA IC, Poveda Conde LC, Acosta Pelaez JD, Fernandez Velez FR, et al
    Giant Pulmonary Artery Aneurysm in Chronic Thromboembolic Pulmonary Hypertension: Multimodality Imaging of a Rare Complication.
    JACC Case Rep. 2026 Jul 2:109129. doi: 10.1016/j.jaccas.2026.109129.
    PubMed    
    Abstract available
    
    

13. TAMURA Y, Kusunose K, Yamashita Y, Akagi T, et al
    JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis.
    Circ J. 2026 Jun 30. doi: 10.1253/circj.CJ-25-1144.
    PubMed    
    
    
    

14. TRAN HV, Van Dreumel C, Schafer A, Mukherjee M, et al
    Blood Pressure Change After Six-minute Walk Test Is an Independent Predictor of Clinical Worsening in Patients with Pulmonary Hypertension.
    Ann Am Thorac Soc. 2026 Jul 1:aaoag178. doi: 10.1093.
    PubMed    
    
    
    

15. ABUSIDO T, Alshaibi S, Aldraihem A, Alfadhel A, et al
    Late presentation of alveolar capillary dysplasia with misalignment of pulmonary veins presenting as refractory pulmonary hypertension in infancy.
    Respir Med Case Rep. 2026;62:102456.
    PubMed    
    Abstract available
    
    

16. HA MN, Thuillet R, Ottaviani M, Normand C, et al
    Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension.
    Cardiovasc Res. 2026 Jul 1:cvag147. doi: 10.1093.
    PubMed    
    Abstract available
    
    

17. VOLKOV AV, Yudkina NN, Nikolaeva EV, Nasonov EL, et al
    [Initial disorders of pulmonary hemodynamics in patients with systemic sclerosis: the relevance of the new hemodynamic definition of pulmonary arterial hypertension].
    Ter Arkh. 2026;98:275-281.
    PubMed    
    Abstract available
    
    

18. MAHASHABDE ML, Guniganti SK, Saketh BVN
    Perfect diagnostic accuracy in a small derivation cohort and outdated classification criteria: Methodological concerns regarding miR-21 as a biomarker for chronic obstructive pulmonary disease-associated pulmonary hypertension.
    Lung India. 2026;43:481-482.
    PubMed    
    
    
    

19. JIANG XH, Yang YH, Yang SQ, Guo XJ, et al
    [Dyspnea, pulmonary mosaic sign and pulmonary hypertension].
    Zhonghua Jie He He Hu Xi Za Zhi. 2026;49:762-767.
    PubMed    
    Abstract available
    
    

20. QIAN J, Song C, Yuan M, Bai Y, et al
    Integrated Mindfulness and Cardiopulmonary Rehabilitation Improves Cardiopulmonary Performance and Psychological Stress in Pulmonary Arterial Hypertension.
    Can Respir J. 2026;2026:e3058088.
    PubMed    
    Abstract available
    
    

21. KAGAMI K, Yuasa N, Harada T, Tani Y, et al
    Echocardiography-Derived Exercise Pulmonary Hypertension and Longitudinal Changes in Pulmonary Artery Pressures in Systemic Sclerosis: A Non-Invasive Assessment for Risk Stratification.
    Pulm Circ. 2026;16:e70282.
    PubMed    
    Abstract available
    
    

22. WANG DW, Katayama A, Ligon MM, Crowley SE, et al
    Incidence of Adverse Cardiac Events After Liver Transplantation in Patients With Different Hemodynamic Classifications of Pulmonary Hypertension.
    Int J Hepatol. 2026;2026:2869285.
    PubMed    
    Abstract available
    
    

23. SALEEMI S, Alameer R, Alsulaim T, Alghasab N, et al
    Prevalence of Anxiety and Depression in Patients With Pulmonary Hypertension and Their Impact on Health-Related Quality of Life: A Prospective Cross-Sectional Observational Study.
    Cureus. 2026;18:e109819.
    PubMed    
    Abstract available
    
    

24. CHEN R, Chen X, Liang L, Li H, et al
    HO-1-modified umbilical cord MSCs alleviate pulmonary arterial hypertension by reducing inflammation and endothelial dysfunction.
    Stem Cells Transl Med. 2026;15:szag036.
    PubMed    
    Abstract available
    
    

25. SPERRY BW, Carlino I, Palazzuoli A
    Beyond vasodilation: sotatercept and the remodeling hypothesis in hfpef-associated pulmonary hypertension.
    Heart Fail Rev. 2026;31:76.
    PubMed    
    Abstract available
    
    

26. FENG H, Liu Y, Hu W, Zou J, et al
    IL-22BP attenuates right ventricular remodeling in pulmonary arterial hypertension.
    Clin Sci (Lond). 2026;140:1575-1597.
    PubMed    
    Abstract available
    
    

27. PALMERT T, Hui W, Simpkin CT, Dragulescu A, et al
    Association between hepatic vein Doppler and echocardiographic diastolic indices with invasively measured right ventricular filling pressures in pediatric pulmonary arterial hypertension.
    Int J Cardiol. 2026;460:134619.
    PubMed    
    Abstract available
    
    

28. BLAKE MJ, Prins SE, Blake J, Hartweck LM, et al
    Pulmonary arterial hypertension induces a metabolic and inflammatory hepatopathy.
    J Clin Invest. 2026;136:e201862.
    PubMed    
    Abstract available
    
    

29. LI M, Wang Y, Hu X, Zhao H, et al
    Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children.
    BMC Pediatr. 2026;26:601.
    PubMed    
    Abstract available
    
    

30. CHEN J, Chen W, Li Z, Luo J, et al
    Prognostic significance of circulating level of GRP78 in pulmonary arterial hypertension.
    BMC Cardiovasc Disord. 2026;26:513.
    PubMed    
    Abstract available
    
    

31. GAO X, Yang Y, Guo L, Wang L, et al
    TCONS_00052110 is associated with prolonged PTBP1 half-life and mitochondrial injury in PAH-associated right ventricular stress.
    Sci Rep. 2026;16:19892.
    PubMed    
    Abstract available
    
    

32. IKWUANUSI E, Rajah T, Scandrett K, Asamane EA, et al
    Perioperative management of pulmonary arterial hypertension in children undergoing congenital heart surgery: a systematic review and meta-analysis.
    J Cardiothorac Surg. 2026;21:420.
    PubMed    
    Abstract available
    
    

33. CHEN L, Wang C, Li J, Lv L, et al
    Pulmonary arterial hypertension caused by compression of the left lower pulmonary vein in children.
    J Cardiothorac Surg. 2026;21:376.
    PubMed    
    Abstract available
    
    

34. ZHENG YM, Jiang JQ, Li X, Huang HB, et al
    Novel KCNK3 variant in a child with pulmonary arterial hypertension.
    Hereditas. 2026;163:67.
    PubMed    
    Abstract available
    
    

35. SALIK DEMIRTAS N, Loku E, Porschen Y, Schaffer J, et al
    Hypoxia or tobacco-smoke exposure induce region-specific microvascular remodeling in the brain.
    Sci Rep. 2026;16:12722.
    PubMed    
    Abstract available
    
    

36. CARMONA-SEGOVIA AD, Morales-Asencio JM, Escribano-Subias P, Rodriguez-Capitan J, et al
    Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
    Health Qual Life Outcomes. 2026;24:76.
    PubMed    
    Abstract available
    
    

37. SHINYA Y, Hiraide T, Momoi M, Goto S, et al
    Experimental pulmonary arterial hypertension in mice with a pathogenic SOX17 variant.
    Sci Rep. 2026;16:16168.
    PubMed    
    Abstract available
    
    

38. BARBOSA VM, Santos RT, Dos Santos de Assumpcao L, Correa AMC, et al
    Neuroinflammation, blood-brain barrier dysfunction, and cognitive decline in pulmonary arterial hypertension: an experimental study.
    Sci Rep. 2026;16:17251.
    PubMed    
    Abstract available
    
    

39. CHEN K, Li Z, Lu J, Guo Y, et al
    Activation of alpha7nAChR prevents maladaptive right ventricular remodeling via inhibiting the recruitment of CCR2(+) macrophages in experimental pulmonary arterial hypertension.
    Respir Res. 2026;27:206.
    PubMed    
    Abstract available
    
    

40. HU B, Chen S, Dong L
    The mechanism of S100A4 regulating Fibulin-5 expression to promote the proliferation and migration of PASMCs.
    Sleep Breath. 2026;30:116.
    PubMed    
    Abstract available
    
    

41. QIAN Z, Kan J, Chen Y, Ye P, et al
    CircATXN2 exacerbates pulmonary arterial hypertension by modulating the miR-138-5p/SMURF1 axis.
    Respir Res. 2026;27:203.
    PubMed    
    Abstract available
    
    

42. GAO S, Zhao S, Wang Y, Liu Y, et al
    CHI3L1: a novel regulator of vascular remodeling in pulmonary arterial hypertension.
    Mol Cell Biochem. 2026;481:2063-2081.
    PubMed    
    Abstract available
    
    

43. GENG X, Wang Z, Liu Y, Zhu J, et al
    Construction and validation of high altitude pulmonary edema prediction models based on deep learning and quantitative analysis of X-ray images.
    BMC Med Imaging. 2026;26:235.
    PubMed    
    Abstract available
    
    

44. NASIR M, Markos S
    Survival and mortality predictors among adults with rheumatic heart disease in ethiopia: a 10-year retrospective cohort study.
    BMC Cardiovasc Disord. 2026;26:383.
    PubMed    
    Abstract available
    
    

45. ENGOLE YM, Makanzu B, Mvunzi TS, Makulo JR, et al
    Elevated tricuspid regurgitation velocity in adults with sickle cell disease and HbAA controls in Kinshasa, Democratic Republic of the Congo: a comparative cross-sectional study.
    Ann Hematol. 2026;105:192.
    PubMed    
    Abstract available
    
    

46. WANDE Y, Qianqian C, Yi W, Minghui Z, et al
    S- nitrosylation of Annexin A2 at Cys133 ameliorates pulmonary arterial hypertension by inhibiting the WNT/beta-catenin pathway.
    Respir Res. 2026;27:217.
    PubMed    
    Abstract available
    
    

47. UYANER KAN M, Kan H, Alsancak Y, Alkan Baylan F, et al
    Mitral stenosis severity and the hypoxic response: potential role of hypoxia-inducible factor-2alpha - a cross-sectional study.
    BMC Cardiovasc Disord. 2026;26:348.
    PubMed    
    Abstract available
    
    

48. PALMERI S, Lancieri M, Ferro J, Salvati P, et al
    Efficacy of combined JAK1/2 inhibition and cyclosporine in paediatric-onset Still's disease with lung involvement: a case report.
    Pediatr Rheumatol Online J. 2026;24:27.
    PubMed    
    Abstract available
    
    

49. RATTANATHANYA H, Binetti A, Pohlin F, Ferreira SCM, et al
    Cardiovascular effects of a selective 5-HT4 agonist and an alpha-2 adrenoceptor antagonist in etorphine immobilised sheep (Ovis aries) - a randomised, prospective, and controlled trial.
    BMC Vet Res. 2026;22:224.
    PubMed    
    Abstract available
    
    

50. GIANI M, Bombino M, Ravasi M, Fumagalli B, et al
    Early trajectories of pulmonary hemodynamics in ARDS patients undergoing V-V ECMO: key determinants and prognostic impact.
    Crit Care. 2026;30:156.
    PubMed    
    Abstract available
    
    

51. REPSOLD L, Harutyunova S, Grunig E, Benjamin N, et al
    Reduced gastrointestinal iron uptake in pulmonary arterial hypertension: a prospective cross-sectional study.
    Respir Res. 2026;27:159.
    PubMed    
    Abstract available
    
    

52. CATON T, Pescatore J, Naranjo M, Gayen S, et al
    Pulmonary vasodilator therapy is associated with improved survival in COPD-PH with pulmonary vascular predominance.
    BMC Pulm Med. 2026;26:154.
    PubMed    
    Abstract available
    
    

53. AUEYINGSAK S, Khankaew K, Teerawattananant W, Singsangtam P, et al
    Validity and reliability testing of the Thai version of the emPHasis-10 questionnaire for patients with pulmonary arterial hypertension.
    J Patient Rep Outcomes. 2026;10:30.
    PubMed    
    Abstract available
    
    

54. WU R, Wang K, Fan M, Jia R, et al
    Multi-omics integration study of vascular smooth muscle cell phenotypic conversion identified novel biomarkers in idiopathic pulmonary arterial hypertension.
    Respir Res. 2026;27:135.
    PubMed    
    Abstract available
    
    

55. BAI HJ, Wang YW, Li ZQ, Lu DX, et al
    Perillyl alcohol attenuates hypoxia induced right ventricular dysfunction and remodeling by balancing the renin angiotensin aldosterone system in rats.
    Sci Rep. 2026;16:5417.
    PubMed    
    Abstract available
    
    

56. CHEN W, Luo X, Luo J, Song J, et al
    Clinical relevance of the TAPSE/SPAP ratio in pulmonary arterial hypertension: a single-center retrospective study.
    BMC Cardiovasc Disord. 2026;26:190.
    PubMed    
    Abstract available
    
    

57. BILGIC S, Vardaloglu I, Koroglu I, Karayel E, et al
    Perfusion-only Q-SPECT as a rule-out tool for CTEPH in resource-limited settings: a feasibility study on reducing unnecessary referrals to tertiary centers.
    BMC Pulm Med. 2026;26:72.
    PubMed    
    Abstract available
    
    

58. KUNSTYR J, Niznansky M, Prskavec T, Votruba J, et al
    Management of airway hemorrhage with endobronchial valve in patients undergoing pulmonary endarterectomy- an expert center experience: a case report.
    BMC Anesthesiol. 2026;26:124.
    PubMed    
    Abstract available
    
    

59. JINZHONG H, Chenxi L, Xiaojun L, Chengying H, et al
    Extracorporeal membrane oxygenation for pulmonary arterial hypertension complicating pregnancy: case series and literature review.
    BMC Pregnancy Childbirth. 2026;26:148.
    PubMed    
    Abstract available
    
    

60. TAMURA Y, Kumamaru H, Murakami K, Matsuoka K, et al
    Real-world treatment practices of selexipag and parenteral prostacyclin (PGI(2)) analogs for pulmonary arterial hypertension in Japan: Retrospective study of the Japan PH Registry.
    J Cardiol. 2026;88:29-37.
    PubMed    
    Abstract available
    
    

61. LUPPINO-ASSAD AP, Vidaurre R, Camata O, Miossi R, et al
    Impact of male sex in clinical and laboratory features of systemic sclerosis.
    Adv Rheumatol. 2026;66:12.
    PubMed    
    Abstract available
    
    

62. WU Y, Qian Y, Quan R, Yang Y, et al
    Ten-year survival, trends and risk stratification of newly diagnosed idiopathic pulmonary arterial hypertension in China: insights from a national multicenter prospective registry.
    BMC Pulm Med. 2025;25:547.
    PubMed    
    Abstract available
    
    

63. CHEN G, Zhang Q, Geng L, Zhang Y, et al
    Risk factors of incident lung diseases and the impact of DMARDs in rheumatoid arthritis patients: a longitudinal study.
    BMC Pulm Med. 2025;25:504.
    PubMed    
    Abstract available
    
    

64. AUSBUETTEL F, Kano F, Patsalis N, Fichera C, et al
    Prediction of long-term survival in patients with concomitant pulmonary hypertension and its subtypes after successful transcatheter edge-to-edge mitral valve repair.
    Cardiovasc Diagn Ther. 2026;16:49.
    PubMed    
    Abstract available
    
    

65. MIHAI A
    Comment on: "Echocardiography-Derived Exercise Pulmonary Hypertension and Longitudinal Changes in Pulmonary Artery Pressures in Systemic Sclerosis".
    Pulm Circ. 2026;16:e70291.
    PubMed    
    
    
    

66. AKAGI S, Kondo M, Ichimura K, Tanaka T, et al
    Recurrence of Pulmonary Hypertension After Unilateral Lung Transplantation: Histological Evidence of Vasoconstrictive Mechanism.
    Pulm Circ. 2026;16:e70289.
    PubMed    
    Abstract available
    
    

67. HINTZ L, Stampouloglou A, Rangaswami J, Lo KB, et al
    Renal Recovery Patterns and Long-Term Kidney Function Decline in Pulmonary Hypertension.
    Pulm Circ. 2026;16:e70336.
    PubMed    
    Abstract available
    
    

68. YILDIRIM F, Ok E, Unver V, Sezgin D, et al
    Quality of Life Outcomes in Patients with Pulmonary Hypertension Receiving Prostacyclin Therapy: Impact of Anxiety, Depression, Sociodemographic Characteristics, and Treatment-Related Factors.
    Turk Kardiyol Dern Ars. 2026 Jul 10. doi: 10.5543/tkda.2026.01628.
    PubMed    
    Abstract available
    
    

69. 
    [Clinical application of echocardiography in the diagnosis and treatment of adult pulmonary hypertension: a Chinese guideline (2026)].
    Zhonghua Nei Ke Za Zhi. 2026;65:681-696.
    PubMed    
    Abstract available
    
    

70. DE OLIVEIRA NASCIMENTO IA, Carvalho GG, Zorze Rossetto N, Cauzzo IS, et al
    Inhaled Iloprost for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease: A Real-World Longitudinal Cohort Study.
    Respir Med. 2026 Jul 9:109028. doi: 10.1016/j.rmed.2026.109028.
    PubMed    
    Abstract available
    
    

71. SUASTIARI NPW, Rahmania R, Utama R
    Beyond the Irregular Beat: An Unexpected Case of Raynaud's Phenomenon in a Patient with Atrial Fibrillation.
    Acta Med Indones. 2026;58:277-280.
    PubMed    
    Abstract available
    
    

72. HUA C, Huang W, Chen Z, Cai X, et al
    Effects of different exercise-based rehabilitation programs in adults with pulmonary arterial hypertension and related pulmonary hypertension populations: a systematic review and network meta-analysis.
    BMC Sports Sci Med Rehabil. 2026 Jul 8. doi: 10.1186/s13102-026-01864.
    PubMed    
    Abstract available
    
    

73. DIAZ G, Lawrence A, Ossi J, Arungwa D, et al
    Clinical Updates in Pulmonary Hypertension.
    Rev Cardiovasc Med. 2026;27:48374.
    PubMed    
    Abstract available
    
    

74. BIANCOSINO C, Firat AE, Redwan B
    Chronic Thromboembolic Pulmonary Hypertension as an Inflammation-Angiogenesis Disorder: From Thrombus Persistence to Dual Pulmonary Vasculopathy.
    Rev Cardiovasc Med. 2026;27:49832.
    PubMed    
    Abstract available
    
    

75. SUN M, Zang D, Chen J
    Long-acting relaxin for pulmonary hypertension: from systemic pharmacodynamics to disease-site pharmacology.
    Br J Pharmacol. 2026 Jul 7. doi: 10.1111/bph.70595.
    PubMed    
    
    
    

76. LI XM, Qiu LH, Zhang SX, Zhou YP, et al
    Right Atrial Function Predicts Outcomes of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension.
    JACC Asia. 2026;6:1264-1267.
    PubMed    
    
    
    

77. JEONG J, Lee BS, Eun H, Shin SH, et al
    Preliminary Report of a Nationwide Prospective Cohort of Congenital Diaphragmatic Hernia in Korea.
    J Korean Med Sci. 2026;41:e188.
    PubMed    
    Abstract available
    
    

78. SOLMAZ H, Uludag B, Colak A
    The predictive value of the systemic immune-inflammation index in chronic thromboembolic pulmonary hypertension.
    Medicine (Baltimore). 2026;105:e49689.
    PubMed    
    Abstract available
    
    

79. GIFFA C, Courat-Beuvon S, Croquette M, Larrieu-Ardilouze E, et al
    Effectiveness and tolerance of respiratory rehabilitation in suspected pulmonary hypertension associated with chronic obstructive pulmonary disease.
    Respir Med Res. 2026;90:101297.
    PubMed    
    Abstract available
    
    

80. GREELEY A, Chuang K, Larsen T, Patel S, et al
    Unexpected Right Ventricular Uptake: A Sign of Pulmonary Hypertension from a Large Pulmonary Embolism.
    J Brown Hosp Med. 2026;5:163427.
    PubMed    
    Abstract available
    
    

81. WANG N, Xing J, Zheng Y, Wang J, et al
    The Predictive Value of the Combined FVC/DLCO Ratio and 1-Minute Heart Rate Recovery After Exercise in Stable Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.
    Int J Gen Med. 2026;19:610100.
    PubMed    
    Abstract available
    
    

82. ARMSTRONG I, Winter P
    The ethical application of artificial intelligence in digital health: patients' knowledge, pulmonary hypertension, and the problem of misrecognition.
    Eur Heart J Digit Health. 2026;7:ztag087.
    PubMed    
    Abstract available
    
    

83. ISHII T, Tani Y, Kagami K, Yuasa N, et al
    Isolated increases in tricuspid regurgitation velocity during exercise in dyspneic patients without risks for pulmonary hypertension.
    J Echocardiogr. 2026 Jul 4. doi: 10.1007/s12574-026-00743.
    PubMed    
    Abstract available
    
    

84. KABAKCIOGLU DC, Kasavi C
    Network-Based Multiomics Integration Reveals Immunometabolic Convergence Between COVID-19 and Pulmonary Arterial Hypertension.
    OMICS. 2026;30:479-491.
    PubMed    
    Abstract available
    
    

85. HOU X, Jiang X, Meng X, Zhou J, et al
    Cx43 mediates nicotine-induced enhancement of mouse pulmonary arterial tone by downregulating Kv1.2 and Kv2.1 channels.
    Food Chem Toxicol. 2026;215:116182.
    PubMed    
    Abstract available
    
    

86. PLATANIAS K, Soulaidopoulos S, Sagris M, Makris A, et al
    Interventional strategies for pulmonary arterial hypertension: Current perspectives and future directions.
    Hypertens Res. 2026;49:2181-2189.
    PubMed    
    Abstract available
    
    

87. CHAN JOINER H, Pande SA, Szafranski P, Sen P, et al
    Small partial deletion of a highly GC-rich FOXF1 exon 1 in two deceased siblings with alveolar capillary dysplasia.
    Genomics. 2026;118:111259.
    PubMed    
    Abstract available
    
    

88. RAFFENSPERGER K, Bueno M, Philips BJ, Miller M, et al
    Endothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis.
    JCI Insight. 2026;11:e200198.
    PubMed    
    Abstract available
    
    

89. BALAKRISHNAN B, Marakini A, Detloff L, Mahalwar G, et al
    Invasive Cardiopulmonary Exercise Testing Identifies Distinctive Hemodynamic Phenotypes in Patients with Interstitial Lung Disease and Exercise Intolerance.
    Respiration. 2026;105:715-726.
    PubMed    
    Abstract available
    
    

90. SHEN S, Yan B, Li Y, Jiang J, et al
    Berberine alleviates acute embolism-induced lung inflammation and injury by suppressing miR-22-5p expression and modulating the TLR4/NF-kappaB signaling pathway.
    Toxicol Appl Pharmacol. 2025;505:117563.
    PubMed    
    Abstract available
    
    

91. LU X, Hu H, Liu Y, Guo Z, et al
    5-HT(2a)R contributes to pulmonary arterial hypertension by modulating the AHR pathway.
    Biochem Pharmacol. 2025;242.
    PubMed    
    Abstract available
    
    

92. SU X, Yu C, Liu J
    Reversible severe pulmonary hypertension triggered by atrioventricular dyssynchrony in complete heart block: a case report.
    BMC Cardiovasc Disord. 2026 Jul 17. doi: 10.1186/s12872-026-05999.
    PubMed    
    Abstract available
    
    

93. BOGER R
    Reclustering of Pulmonary Hypertension Patients Along Molecular Pathophysiology Traits Better Predicts Long-Term Outcome Than Currently Used Classification.
    J Am Heart Assoc. 2026 Jul 17:e052334. doi: 10.1161/JAHA.126.052334.
    PubMed    
    
    
    

94. FARHA S, Hu B, Chen R, Barnard J, et al
    Endotypes of Vascular Health Predict Transplantation-Free Survival in Pulmonary Hypertension.
    J Am Heart Assoc. 2026 Jul 17:e048795. doi: 10.1161/JAHA.125.048795.
    PubMed    
    Abstract available
    
    

95. ZHAO Y, An Y, Yang Q, Ma Z, et al
    Immunological coagulation dual axis stratification identifies ultra high-risk phenotypes in systemic sclerosis.
    Front Immunol. 2026;17:1866374.
    PubMed    
    Abstract available
    
    

96. LIN CY, Gaweda B, Manthatis N, Sreedhar S, et al
    The Tricuspid Valve Maladapts in a Pulmonary Hypertension Rat Model.
    bioRxiv [Preprint]. 2026 Jul 12:2026.07.08.737279.
    PubMed    
    Abstract available
    
    

97. ZHANG Y, Feng S, Zhang Y, Luo J, et al
    Development and internal validation of an interpretable machine learning model using routine laboratory data for systemic sclerosis-associated pulmonary arterial hypertension.
    Rheumatol Int. 2026;46:213.
    PubMed    
    Abstract available
    
    

98. BHARDWAJ A, Valadi Ramakrishnan S, Joseph D, Nathan S, et al
    High-Output Heart Failure and Pulmonary Hypertension Caused by Arteriovenous Graft: Diagnosis and Treatment.
    JACC Case Rep. 2026 Jul 15:109095. doi: 10.1016/j.jaccas.2026.109095.
    PubMed    
    Abstract available
    
    

99. WANG XB, Gao ZQ, Yu Y, Lu YF, et al
    Differences in systemic inflammation and prethrombotic biomarkers between AECOPD patients with and without pulmonary hypertension.
    J Inflamm (Lond). 2026 Jul 15. doi: 10.1186/s12950-026-00508.
    PubMed    
    Abstract available
    
    

100. WANG W, Zhao T, Wang YM, Xie O, et al
     [Role of miR-146b-5p in hyperoxia-induced pulmonary vascular remodeling in neonatal rats: mechanisms based on the regulation of ferroptosis].
     Zhongguo Dang Dai Er Ke Za Zhi. 2026;28:885-892.
     PubMed    
     Abstract available
     
     

101. BATTILANA B, Stoeck CT, Robert F, Senbaklavaci O, et al
     Minimally Invasive Porcine Model for Chronic Thromboembolic Pulmonary Hypertension.
     Pulm Circ. 2026;16:e70344.
     PubMed    
     Abstract available
     
     

102. ZHYVYLO I, Sood N, Pugashetti JV, Linderholm AL, et al
     Smoking-Related Clinical and Molecular Abnormalities in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension.
     Pulm Circ. 2026;16:e70349.
     PubMed    
     Abstract available
     
     

103. AVITABILE CM, Butler K, Mondal A, Frank DB, et al
     Right Ventricular Function Improves With Pulmonary Vasodilator Treatment in Pediatric Patients With Pulmonary Hypertension and Multivessel Pulmonary Vein Stenosis in a Single Center Cohort.
     Pulm Circ. 2026;16:e70346.
     PubMed    
     Abstract available
     
     

104. HU J, Qiao Y, Lei G, Gai X, et al
     Serum Pharmacochemistry-Guided DARTS-MS Profiling Reveals Potential Mechanisms of Caragana jubata Against Hypoxic Pulmonary Hypertension.
     Int J Mol Sci. 2026;27:5815.
     PubMed    
     Abstract available
     
     

105. SANDERS R, Walsh T, Baird GL, Atalay MK, et al
     Effects of Dehydroepiandrosterone in Pulmonary Hypertension (EDIPHY): A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
     Ann Am Thorac Soc. 2026 Jul 14:aaoag195. doi: 10.1093.
     PubMed    
     Abstract available
     
     

106. SONG J, Bian X, Zhuang B, Liu X, et al
     Risk Factors for Pulmonary Hypertension and Survival in Hemodialysis Patients: Are We Overlooking Serum Magnesium?
     Kidney Dis (Basel). 2026;12:554-563.
     PubMed    
     Abstract available
     
     

107. BACHAR R, Tager D, Berro J, Nero N, et al
     Pulmonary hypertension following lung transplant: a systematic review.
     J Thorac Dis. 2026;18:685.
     PubMed    
     Abstract available
     
     

108. LI F, Ma X, Li R, Li B, et al
     Identification of neutrophil extracellular traps-related genes as feature genes and potential therapeutic targets in pulmonary hypertension.
     J Thorac Dis. 2026;18:627.
     PubMed    
     Abstract available
     
     

109. GESANG Q, Danzeng Z, Suona Y, Luo Q, et al
     Epidemiological patterns of pulmonary hypertension at 3,658 meters: insights from a Tibet plateau retrospective study.
     J Thorac Dis. 2026;18:633.
     PubMed    
     Abstract available
     
     

110. WU H, Zhou R, Hui W, Qiao S, et al
     Hypoxia-injured pulmonary vascular targeting and microenvironment-responsive nanoparticle to treat hypoxic pulmonary hypertension.
     J Nanobiotechnology. 2026 Jul 13. doi: 10.1186/s12951-026-04680.
     PubMed    
     Abstract available
     
     

111. FUCHIGAMI Y
     Machine-Reported Electrocardiographic Right Axis Deviation or Right Ventricular Hypertrophy and Echocardiographic Pulmonary Hypertension Phenotypes and Right-Heart Abnormalities.
     Echocardiography. 2026;43:e70539.
     PubMed    
     Abstract available
     
     

112. DAI X, Fan R, Zhang J, Guo D, et al
     Multimodal model for predicting exercise-induced pulmonary hypertension validated by invasive exercise hemodynamics: a prospective study.
     Respir Res. 2026 Jul 11. doi: 10.1186/s12931-026-03814.
     PubMed    
     Abstract available
     
     

113. YAO M, Chen R, Shen M, Xu Z, et al
     TRAF6 promotes pulmonary hypertension by enhancing K63-linked ubiquitination and activation of STAT3.
     Front Pharmacol. 2026;17:1850163.
     PubMed    
     Abstract available
     
     

114. MU L, Yuan H, Zhang J, Wu J, et al
     SPP1 improves early risk assessment of postpartum adverse events in pulmonary arterial hypertension complicated with pregnancy.
     Eur J Obstet Gynecol Reprod Biol. 2026;324:115254.
     PubMed    
     Abstract available
     
     

115. ALGHOUNAIM M, Shaheen NA, Aldaithan A, Awlad Thani S, et al
     Clinical phenotypes and mortality predictors in pediatric critical pertussis: A multinational study.
     J Infect Public Health. 2026;19:103276.
     PubMed    
     Abstract available
     
     

116. DHANANI Z, Vorselaars AD, Gupta R, Spagnolo P, et al
     When the lung is at risk: diagnosis, manifestations, and complications of pulmonary sarcoidosis.
     Curr Opin Immunol. 2026;101:102792.
     PubMed    
     Abstract available
     
     

117. OLANIRAN KO, Nero AC, Toto RD
     Estimated glomerular filtration rate discordance and cardiopulmonary morbidity in sickle cell disease.
     Blood Adv. 2026;10:5033-5044.
     PubMed    
     Abstract available
     
     

118. ZHAO S, Lu ZY, Zhou P, Xiong L, et al
     Early postoperative treprostinil in for severe pulmonary arterial hypertension in a high-risk pediatric patient with complete atrioventricular septal defect: a case report.
     BMC Cardiovasc Disord. 2026;26:600.
     PubMed    
     Abstract available
     
     

119. IDEI S, Tanaka Y, Dong F, Okamura K, et al
     Pulmonary vascular resistance is associated with two-year clinical outcomes in non-hypoxemic COPD with mild pulmonary hemodynamic abnormalities.
     Respir Investig. 2026;64:101450.
     PubMed    
     Abstract available
     
     

120. ALSUMALI A, Pontinha VM, Cohen BG, Levy M, et al
     Application of a Prevalence-Adjusted Cost-Effectiveness Threshold Framework for Pulmonary Arterial Hypertension.
     Pharmacoeconomics. 2026;44:975-983.
     PubMed    
     Abstract available
     
     

121. ANDROSHCHUK V, Long E, Chehab O, Wilcox J, et al
     Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Implantation: The Prognostic Effect of Right-sided cardiopulmonary Remodelling.
     Can J Cardiol. 2026;42:1458-1468.
     PubMed    
     Abstract available
     
     

122. KROWKA MJ, DuBrock HM, Raevens S, Fallon MB, et al
     Unmet needs in diagnosis and management of portopulmonary hypertension: How far have we reached?
     Hepatology. 2026;84:573-581.
     PubMed    
     Abstract available
     
     

123. MARTINS ER, Carvalho AA, Botelho LFB, Medeiros Filho JEM, et al
     Hepatic Elastography as a Noninvasive Marker of Right Ventricular Dysfunction and Prognosis in Precapillary Pulmonary Hypertension: A Pilot Study.
     Respir Med. 2026 Jul 24:109043. doi: 10.1016/j.rmed.2026.109043.
     PubMed    
     Abstract available
     
     

124. LI Y, Ye P, Ming B, Huang S, et al
     Synergistic improvements in mental health status and cardiopulmonary performance in patients with connective tissue disease-associated pulmonary hypertension.
     Respir Med. 2026 Jul 24:109061. doi: 10.1016/j.rmed.2026.109061.
     PubMed    
     Abstract available
     
     

125. ZAYED AA, Aldalahmeh M, Barakat S, Khattar G, et al
     Prevalence and Impact of Pulmonary Hypertension Associated with Arteriovenous Fistulas and Grafts in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
     Adv Respir Med. 2026;94:46.
     PubMed    
     Abstract available
     
     

126. COPPI F, Pagnoni G, Nassar A, de Pinto M, et al
     Why Men Fare Worse: Understanding Gender Disparities in Systemic Sclerosis-Associated Pulmonary Hypertension.
     Clin Med Insights Cardiol. 2026;20:11795468251396355.
     PubMed    
     Abstract available
     
     

127. HUTTAYANANONT S, Panprom C, Sarikan S, Tantisak R, et al
     Associations of C-reactive protein and neutrophil-to-lymphocyte ratio with cardiac remodeling, pulmonary hypertension, and survival outcomes in dogs with myxomatous mitral valve disease.
     Vet World. 2026;19:2279-2292.
     PubMed    
     Abstract available
     
     

128. JIANG S, Han X, He Y, Gao Q, et al
     Meta-analysis of prostacyclin therapy for persistent pulmonary hypertension with congenital diaphragmatic hernia.
     J Pediatr Surg. 2026 Jul 23:163301. doi: 10.1016/j.jpedsurg.2026.163301.
     PubMed    
     Abstract available
     
     

129. AZARINE A, Sakhi H, Chevance V, Montani D, et al
     Pulmonary hypertension phenotyping with cardiac MRI: Can myocardial tissue characterization refine clinical classification?
     Respir Med Res. 2026;90:101298.
     PubMed    
     
     
     

130. CAO L, Teng W, Sang L, Xu X, et al
     The role of soluble suppression of tumorigenicity 2 in pulmonary hypertension: a systematic review and meta-analysis.
     Am Heart J Plus. 2026;68:100827.
     PubMed    
     Abstract available
     
     

131. FENG X, Wang F, Yang T, Yu S, et al
     LncRNA APF suppresses pulmonary vascular remodeling in chronic thromboembolic pulmonary hypertension through the miR-188-3p/ATG7-mediated autophagy pathway.
     Am J Transl Res. 2026;18:4964-4977.
     PubMed    
     Abstract available
     
     

132. BREDECK G, Cruz-Utrilla A, Oliver E
     Breakthroughs in our molecular understanding of therapeutic targets for pulmonary hypertension.
     Expert Opin Ther Targets. 2026 Jul 23. doi: 10.1080/14728222.2026.2709796.
     PubMed    
     Abstract available
     
     

133. PENG Y, Yang J
     Impact of pulmonary hypertension on long-term neurodevelopmental outcomes in preterm neonates with bronchopulmonary dysplasia: A meta-analysis.
     Pak J Med Sci. 2026;42:1860-1868.
     PubMed    
     Abstract available
     
     

134. MANSOUR W, Qiqieh J, Stephan J, Gezahegn S, et al
     A Novel Presentation of Hemodynamic Decompensation With Cardiogenic Shock in a Patient With Partial Anomalous Pulmonary Venous Return.
     Am J Case Rep. 2026;27:e953243.
     PubMed    
     Abstract available
     
     

135. PEREZ DONATE V, Martinez Macias O, Aguilar Escriva A, Peiro Anrubia JE, et al
     Sepsis caused by Staphylococcus argenteus in a patient with severe pulmonary hypertension: A diagnostic challenge for syndromic molecular methods.
     Enferm Infecc Microbiol Clin (Engl Ed). 2026 Jul 22:503229.
     PubMed    
     
     
     

136. TUTTLE M, Pausch C, Pittrow D, McCallum W, et al
     Association Between Invasive Cardiac Hemodynamics and Kidney Function in Patients with Pulmonary Hypertension.
     Kidney360. 2026 Jul 22. doi: 10.34067/KID.0000001271.
     PubMed    
     Abstract available
     
     

137. GIUGGIOLI D, Del Galdo F, D'Alto M, Matucci-Cerinic M, et al
     Towards an integrated and proactive management of pulmonary hypertension in systemic sclerosis: a practical approach for early diagnosis and optimal patient management.
     Rheumatol Adv Pract. 2026;10:rkag077.
     PubMed    
     Abstract available
     
     

138. LEIVA O, Soo S, Liu OC, You V, et al
     Risk factors associated with high probability of pulmonary hypertension in patients with myeloproliferative neoplasms.
     Int J Hematol. 2026 Jul 21. doi: 10.1007/s12185-026-04255.
     PubMed    
     Abstract available
     
     

139. TONG J, Wang A, Wan C, Chen M, et al
     Development and validation of novel prognostic hepatic-cardiac index and hemodynamic prediction models in pre-capillary pulmonary hypertension patients.
     Sci Rep. 2026 Jul 21. doi: 10.1038/s41598-026-62666.
     PubMed    
     Abstract available
     
     

140. HUANG Z, Deng Y, Zeng J, Li D, et al
     Research Progress on the Regulation of Pulmonary Hypertension by the NOTCH3 Signaling Pathway.
     Cardiol Rev. 2026 Feb 9. doi: 10.1097/CRD.0000000000001107.
     PubMed    
     Abstract available
     
     

141. RODRIGUEZ-PLAZA D, Ribas J, Alfaya I, Lopez-Monzoni S, et al
     Development and internal validation of a nomogram to predict pulmonary hypertension in fibrosing interstitial lung diseases.
     BMC Pulm Med. 2026 Jul 20. doi: 10.1186/s12890-026-04495.
     PubMed    
     Abstract available
     
     

142. SALDIVAR L, Garber E, Boubes K, Homsy E, et al
     Reversible pre-capillary pulmonary hypertension due to long-standing arteriovenous fistula.
     Respir Med Case Rep. 2026;63:102467.
     PubMed    
     Abstract available
     
     

143. RIKEN C, Xing C, Limei L, Huan L, et al
     Tracheal delivery of HO-1-modified human umbilical cord-derived mesenchymal stem cells treats pulmonary arterial hypertension by enhancing pulmonary antioxidant and anti-inflammatory responses.
     Transl Res. 2026;295:133-147.
     PubMed    
     Abstract available
     
     

144. YANG T, Chung WJ
     Pulmonary arterial hypertension from a translational perspective: Bridging pathophysiology and treatment.
     Chin Med J (Engl). 2026;139:2070-2083.
     PubMed    
     Abstract available
     
     

145. BOVY V, Alexander P
     Pulmonary vascular changes after lung resection: why less may be more.
     Gen Thorac Cardiovasc Surg. 2026;74:727-736.
     PubMed    
     Abstract available
     
     

146. LINS T, Valzano F, Fliesser E, Borek I, et al
     Transcriptional landscape of pulmonary artery endothelium reveals subpopulation- and disease-specific remodeling signatures.
     Commun Biol. 2026;9:998.
     PubMed    
     Abstract available
     
     

147. REDDY AC, Kaloss AM, Jeong HW, Carvallo-Chaigneau FR, et al
     Pathogenesis, histopathology, and mechanisms of pulmonary pathology secondary to chronic left heart failure in animals.
     J Vet Diagn Invest. 2026;38:755-768.
     PubMed    
     Abstract available
     
     

148. DAUZ JD, Mirani B, Santerre JP, Bendeck MP, et al
     Noninvasive surrogate of main pulmonary artery stiffness is associated with right ventricular function in experimental pulmonary arterial hypertension.
     Am J Physiol Heart Circ Physiol. 2026;331:H335-H348.
     PubMed    
     Abstract available
     
     

149. ZAZZERON L, Tattersfield H, Moore E, Xiao X, et al
     Lifelong Hypoxia Produces Multigenerational Developmental Lung Disease and Pulmonary Hypertension in Mice.
     Am J Physiol Lung Cell Mol Physiol. 2026 Jul 11. doi: 10.1152/ajplung.00199.2026
     PubMed    
     Abstract available
     
     

150. KURIYAMA S, Iwamura C, Kiuchi M, Nagaoka T, et al
     Hypoxia-Induced Epas1-Myl9/12 Axis Shapes the Pathology of Pulmonary Hypertension.
     Circ Res. 2026 Jul 2. doi: 10.1161/CIRCRESAHA.125.327791.
     PubMed    
     Abstract available
     
     

151. KARNES JH, Bao C, Liang S, Thayer T, et al
     Variation in SNX29 and Acute Vasodilator Response in Pulmonary Arterial Hypertension.
     Circ Res. 2026;139:e327117.
     PubMed    
     Abstract available
     
     

152. HUMBERT M, Zeder K, Kovacs G, Weatherald J, et al
     Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives.
     Circulation. 2026;154:156-177.
     PubMed    
     Abstract available
     
     

153. ZHOU J, Yang Z, Huo D
     Echocardiographic Probability of Pulmonary Hypertension, Cardiac Structural Alterations and All-Cause Mortality in Maintenance Hemodialysis Patients: A Single-Center Retrospective Cohort Study With Competing Risk Analysis.
     Clin Cardiol. 2026;49:e70415.
     PubMed    
     Abstract available
     
     

154. NOSSENT EJ, Vonk Noordegraaf A
     Low diffusion capacity in pulmonary hypertension.
     Curr Opin Pulm Med. 2026 Jul 2. doi: 10.1097/MCP.0000000000001290.
     PubMed    
     Abstract available
     
     

155. JHA AK
     High output heart failure in group 1 pulmonary hypertension and clinical outcomes.
     Eur Respir J. 2026;68:2600509.
     PubMed    
     
     
     

156. COOPER D, Turner D, Cooper DS, Hayes D Jr, et al
     Rethinking paracorporeal lung assist device support in the modern era: Why so different than ECMO?
     J Heart Lung Transplant. 2026;45:1238-1240.
     PubMed    
     Abstract available
     
     

157. DIAMOND S, Spray B, Qasim A, Mourani PM, et al
     Novel echocardiographic markers for the assessment of pulmonary hypertension in infants.
     J Perinatol. 2026 Jun 29. doi: 10.1038/s41372-026-02748.
     PubMed    
     Abstract available
     
     

158. DIAMOND SE, Stanford AH, Bischoff AR, McNamara PJ, et al
     Phenotype-based screening algorithm for chronic pulmonary hypertension in preterm infants with bronchopulmonary dysplasia.
     J Perinatol. 2026 Jun 29. doi: 10.1038/s41372-026-02776.
     PubMed    
     Abstract available
     
     

159. UENO K, Kelley D, Tashima T, Dominic J, et al
     Outcomes of donation after circulatory death heart transplantation in recipients with pulmonary hypertension.
     J Thorac Cardiovasc Surg. 2026 Jun 27:S0022-5223(26)00887.
     PubMed    
     Abstract available
     
     

160. SHARMA A, Usman L, Lai JC, Jutras G, et al
     Association of Frailty With Waitlist and Post-Transplant Outcomes in Patients With Hepatopulmonary Syndrome and Portopulmonary Hypertension.
     Transplant Proc. 2026 Jun 18:S0041-1345(26)00268.
     PubMed    
     Abstract available
     
     

161. SCHWIENING M, Gao Q, Southwood M, Crosby A, et al
     Interleukin-6 is critical in the development of pulmonary vascular disease in Gcn2-deficient mice.
     Proc Natl Acad Sci U S A. 2026;123:e2531623123.
     PubMed    
     Abstract available